Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jake Schade(Rutgers, The State University of New Jersey), Sameer A. Parikh(Mayo Clinic), Alan P Skarbnik(Novant Health), Geoffrey Shouse(City Of Hope National Medical Center), Mark R. Dowling(The Royal Melbourne Hospital), Elise A. Chong(Hospital of the University of Pennsylvania), Prioty Islam(Kettering University), John N. Allan(Cornell University), Hamish W. Scott(Walter and Eliza Hall Institute of Medical Research), Deborah M. Stephens(University of North Carolina at Chapel Hill), Philipp W. Raess(Oregon Health & Science University), Aditi Saha(Moffitt Cancer Center), Paul J. Hampel(Mayo Clinic), Kerry A. Rogers(The Ohio State University), Danielle M. Brander(Duke University), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Erin M. Parry(Broad Institute), Matthew J. Matasar(Rutgers, The State University of New Jersey), Seema A. Bhat(The Ohio State University), Mazyar Shadman(University of Washington), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Max Yano(The Ohio State University), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Nikita Malakhov(NewYork–Presbyterian Hospital), Steven R. Hwang(Mayo Clinic), Matthew S. Davids(Dana-Farber Cancer Institute), Meghan C. Thompson(Memorial Sloan Kettering Cancer Center), Alexey V. Danilov(City of Hope), John C. Byrd(University of Cincinnati), Sarah Miller(The Ohio State University), Kari G. Rabe(Mayo Clinic), Philip A. Thompson(The Royal Melbourne Hospital), Ying Huang(Linyi University), Hannah Freedman(Harvard University), Zulfa Omer(University of Cincinnati), Carrie Ho(University of California, San Francisco), Cecelia Miller, Kaitlyn Dvorak‐Kornaus(The Ohio State University), Wei Ding(Mayo Clinic in Arizona), Julio C. Chávez(Moffitt Cancer Center), Yucai Wang(Mayo Clinic), Stephen E. Spurgeon(Oregon Health & Science University)
Cited by 12
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752